Skip to content

Evaluation of U-Net based architectures for synthetic CT generation from dual-contrast MRI

Sep 2026 · Biomedical engineering and physics express · Vol 12 · 0 citations · 36 references
Medicine Physics

Abstract

Deep learning–based MRI-to-CT synthesis supports MR-only radiotherapy and PET/MR attenuation correction, but comparisons of U-Net variants are confounded by differences in datasets, preprocessing, training protocols, and evaluation metrics. This study performed a controlled, tissue-aware, and complexity-aware comparison of five U-Net-based architectures, including U-Net, ResU-Net, Attention U-Net, U-Net++, and attention deep residual U-Net (ADR-U-Net), for brain sCT generation from T1-weighted and FLAIR MRI in 37 subjects from the CERMEP-IDB-MRXFDG database. Subject-level five-fold cross-validation reduced split-dependent bias and prevented slice-level information leakage. Evaluation included mean absolute error (MAE), root mean square error (RMSE), peak signal-to-noise ratio, structural similarity index measure, tissue-specific errors in Hounsfield units (HU), paired Wilcoxon signed-rank tests with Bonferroni correction, and computational complexity analysis. ADR-U-Net achieved the lowest whole-image MAE of 37.38 ± 6.01 HU and RMSE of 109.72 ± 17.35 HU. Its MAE improvement was 1.60 HU relative to ResU-Net, indicating a modest gain over the closest comparator. A focused ADR-U-Net modality-ablation analysis showed lower whole-image MAE with dual-contrast input (37.38 ± 6.01 HU) than with T1-only (40.79 ± 5.00 HU) or FLAIR-only input (38.41 ± 6.30 HU). Bone remained the dominant source of HU error, and U-Net++ had the highest number of floating-point operations without achieving the best accuracy. These findings suggest that model selection should consider tissue-specific HU errors, subject-level robustness, and computational cost. Because no external validation or downstream clinical endpoint was included, the results should be interpreted as controlled within-dataset technical evidence rather than evidence of clinical readiness.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.